Drugs / BB-401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03433027 | Mar → Dec 2018 | head and neck squamous cell carcinoma | Benitec Biopharma, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-12-21 | Benitec Biopharma, Inc. | Results Benitec Provides Update on BB-401 Cancer Treatment Program benitec.com ↗
However, based on the initial analysis, the objective response rate required to support continued patient enrollment into the Phase II study was not achieved. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-12-21 | Benitec Biopharma, Inc. | Benitec Provides Update on BB-401 Cancer Treatment Program benitec.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03433027 ↗ |
| Modality | Antisense oligonucleotide | “Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401)” NCT03433027 ↗ |
| Route | Other | “BB-401 Intratumoral injection” NCT03433027 ↗ |
| Target | EGFR | “Epidermal Growth Factor Receptor (EGFR) AntiSense DNA (BB-401)” NCT03433027 ↗ |